NCT00005044 · CITED IN SOURCE DOCUMENTS

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase: PHASE3
Status at capture: COMPLETED
Registry last update: 2022-06-15

RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Disease-specific Survival (DSS) (10-year Rates Reported)

→

outcome · POSTED

Overall Survival (OS) (10-year Rates Reported)

→

outcome · POSTED

Disease-free Survival (DFS) (10-year Rates Reported)

→

outcome · POSTED

Clinical Patterns of Tumor Recurrence: Time to Locoregional Progression (LRP) and Time to Distant Metastasis (DM) (10 Year Rates Reported)

→

outcome · POSTED

Time to First Biochemical Failure (BF) (10-year Rates Reported)

→

outcome · POSTED

Time to Second Biochemical Failure (SBF) (10-year Rates Reported)

→

outcome · POSTED

Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria 1. Adenocarcinoma of prostatic origin histologically-confirmed within 180 days of the randomization date. 2. Zubrod Performance Status 0-1 (Appendix II). 3. Prostatic biopsy tumor grading by the Gleason Score classification (Appendix VI) is mandatory prior to randomization. 4. Patients at intermediate risk for disease relapse as determined by any of the following combinations of factors (NOTE: tumor found in one or both lobes on biopsy, but not palpable, will not alter T stage): * Clinical stage T1b-4, Gleason score 2-6, and prostate-specific antigen \>10 but ≤ 100. * Clinical stage T1b-4, Gleason score 7, and prostate-specific antigen \< 20. * Clinical stage T1b-1c, Gleason score 8-10, and prostate-specific antigen \<20. 5. Clinically negative (N0) lymph nodes (LN) as established by imaging (pelvic ± abdominal CT, MRI or LAG), or negative LN by nodal sampling or dissection (laparoscopy or laparotomy). Patients with radiologic (e.g., CT, MRI or LAG) or radioimmunoscintigraphy (i.e., ProstaScint™) findings suggestive of regional nodal involvement are eligible if cytologic (e.g., needle aspiration) or histologic (e.g., surgical sampling) evaluation shows no evidence of a neoplastic process (i.e., prostatic or non-prostatic malignancy). Patients with equivocal radiologic findings (maximum nodal size ≤ 1.5 cm) are eligible. 6. No distant (M0) metastases. Patients with radionuclide imaging (e.g., bone scintigraphy, ProstaScint™) findings suggestive, but not diagnostic of metastatic disease are eligible if radiologic (e.g., standard or tomographic radiography, or CT/MRI) imaging does not confirm metastatic disease. 7. Pretherapy serum (total) prostate-specific antigen value performed with a Federal Drug Administration approved assay method, e.g. Abbott, Hybritech, etc. 8. Treatment must begin within 6 weeks after randomization. 9. Alanine aminotransferase (ALT) must be within 2 x upper normal limit. 10. Patients must sign a study-specific informed consent form (Appendix I) prior to randomization. Exclusion Criteria 1. Patients at high risk for disease relapse as determined by either: * Prostate-specific antigen ≥ 20 and Gleason score ≥ 7 (any T stage). * Clinical stage ≥T2 and Gleason score ≥ 8 (any prostate-specific antigen). 2. Patients at low risk for disease relapse as determined by: • Clinical stage ≤T2, Gleason score ≤ 6, and prostate-specific antigen ≤ 10. 3. Clinical stage Tx, T0, or T1a. 4. Histologic or radiologic evidence of tumor involvement of regional lymph nodes (N1) or the presence of metastatic disease (M1). 5. Pretherapy serum prostate-specific antigen level \> 100. 6. Co-morbid medical illness which in the opinion of the investigator is expected to result in a life expectancy of \<10 years. 7. Any of the following prior therapies: * Pelvic external beam radiation therapy. * Radionuclide prostate brachytherapy. * Prostatectomy or prostatic cryosurgery. * Prior bilateral orchiectomy. * Prior androgen suppression therapy; however, patients begun on LHRH agonist therapy remain eligible if (1) LHRH agonists were started no more than 30 days before randomization, and (2) Casodex or Eulexin was (or will be) started no more than 14 days before or after the date that the LHRH agonist injection was given. Any finasteride therapy administered for prostatic hypertrophy must be discontinued. * Chemotherapy for prostatic carcinoma. 8. Previous or concomitant invasive cancer, other than localized basal cell or squamous cell skin carcinoma (AJCC Stage 0-II), unless continually disease free for at least 5 years. 9. Major medical or psychiatric illness which, in the opinion of the investigator, would prevent completion of treatment or would interfere with follow-up. 10. The patient's participation in another medical research study that involves prostate cancer treatment.
healthy Volunteers: false
maximum Age: 120 Years
minimum Age: 18 Years
sex: MALE
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).
intervention Names
Drug: Casodex
Drug: Eulexin
Drug: LHRH agonist
Radiation: radiation therapy
label
TAS x 8 weeks
type
EXPERIMENTAL
description
TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).
intervention Names
Drug: Casodex
Drug: Eulexin
Drug: LHRH agonist
Radiation: radiation therapy
label
TAS x 28 weeks
type
EXPERIMENTAL

interventions

arm Group Labels
TAS x 28 weeks
TAS x 8 weeks
description
Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.
name
Casodex
other Names
bicalutamide
type
DRUG
arm Group Labels
TAS x 28 weeks
TAS x 8 weeks
description
Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.
name
Eulexin
other Names
flutamide
type
DRUG
arm Group Labels
TAS x 28 weeks
TAS x 8 weeks
description
LHRH agonist of choice. The manufacturer's instructions should be followed.
name
LHRH agonist
other Names
Zoladex
Lupron
Eligard
Viadur
luteinizing hormone-releasing hormone (LHRH)-agonist
type
DRUG
arm Group Labels
TAS x 28 weeks
TAS x 8 weeks
description
\[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)\] OR \[regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin\]
name
radiation therapy
type
RADIATION

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 1579
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Disease-specific survival time is measured from date of randomization to death due to prostate cancer based on study chair review, with prostate-cancer death defined as (1) primary cause of death certified as due to prostate cancer, (2) complication of therapy, irrespective of disease status, (3) disease progression in the absence of any anti-tumor therapy, or (4) a 1.0 ng/ml-exceeding-rise in serum prostate-specific antigen (PSA) level on at least two consecutive occasions that occurs during or after salvage androgen suppression therapy. Death due to other causes is considered a competing risk. All others are censored. DSS is estimated using the cumulative incidence method. Ten-year rate is reported.
measure
Disease-specific Survival (DSS) (10-year Rates Reported)
time Frame
From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)

secondary Outcomes

description
Survival time is defined as time from randomization to the date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Ten-year rate is reported.
measure
Overall Survival (OS) (10-year Rates Reported)
time Frame
From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
description
Disease-free survival time is defined as time from randomization to the date of disease progression or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Ten-year rate is reported.
measure
Disease-free Survival (DFS) (10-year Rates Reported)
time Frame
From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
description
Time to distant metastasis measured from date of randomization to date of documented distant metastasis; competing risks are BF, LRP, and death without DM; all others are censored. Time to locoregional progression measured from date of randomization to date of documented local or regional progression; competing risks are BF \[protocol definition- first of (1) the midway date between the last non-rising PSA and the first rising PSA of three consecutive rises or (2) the date of the initiation of salvage hormone therapy\], DM, and death without LRP; all others are censored. LRP and DM are estimated using the cumulative incidence method. Ten -year rates are reported.
measure
Clinical Patterns of Tumor Recurrence: Time to Locoregional Progression (LRP) and Time to Distant Metastasis (DM) (10 Year Rates Reported)
time Frame
From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
description
Protocol definition: Time to BF measured from date of randomization to first of (1) the midway date between the last non-rising PSA and the first rising PSA of three consecutive rises or (2) the date of the initiation of salvage hormone therapy; competing risks are LRP, DM, and death without BF; all others are censored. Phoenix definition: Time to BF measured from date of randomization to first of (1) the date of documented rise of 2 ng/ml above the post-treatment(RT end date) nadir or (2) the date of the initiation of salvage hormone therapy; competing risks are LRP, DM, and death without BF; all others are censored. For both definitions BF is estimated using the cumulative incidence method. Ten year rates reported.
measure
Time to First Biochemical Failure (BF) (10-year Rates Reported)
time Frame
From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
description
Time to SBF measured from date of randomization to the date of PSA increase of ≥1.0 ng/mL (from the nadir PSA after completion of protocol-specified therapy) after salvage androgen suppression was started; competing risks LRP, DM, and death without SBF; all others are censored. SBF is estimated using the cumulative incidence method. Ten-year rates are reported.
measure
Time to Second Biochemical Failure (SBF) (10-year Rates Reported)
time Frame
From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
description
Acute drug therapy and radiation (\<= 90 days from start of RT) toxicity was graded using the Common Toxicity Criteria (CTC) v.2.0 criteria; late toxicity was graded using the Radiation Therapy Oncology Group (RTOG)/European Organisation for Research and Treatment of Cancer (EORTC) Late Radiation Morbidity Scoring schema. Grade refers to the severity of the toxicity. The CTC v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on this general guideline: Grade 1 Mild toxicity, Grade 2 Moderate toxicity, Grade 3 Severe toxicity, Grade 4 Life-threatening or disabling toxicity, Grade 5 Death related to toxicity. The highest grade acute and late toxicity was determined for each patient.
measure
Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient)
time Frame
From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)

Full study description

brief Summary: RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer.
detailed Description: OBJECTIVES: * Compare the efficacy of moderate-duration (28 weeks) neoadjuvant total androgen suppression (TAS) and radiotherapy (RT) with short-duration (8 weeks) neoadjuvant TAS and RT, as related to disease-specific survival, in patients with intermediate-risk adenocarcinoma of the prostate. * Compare these regimens, in terms of overall survival, disease-free survival, time to local tumor progression or distant failure, time to first biochemical failure, hormone-refractory state, and treatment-induced morbidity, in this patient population. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prostate-specific antigen level (no greater than 10 ng/mL vs greater than 10 but no greater than 20 ng/mL vs greater than 20 ng/mL), tumor stage (T1b-2 vs T3-4), Gleason score (2-4 vs 5-6 vs 7-10), and prior hormonal therapy (yes vs no). Patients are randomized to one of two treatment arms. * Arm I: Patients receive total androgen suppression for 8 weeks prior to the initiation of radiotherapy and throughout radiotherapy. A luteinizing hormone-releasing hormone (LHRH) agonist is administered every 1-3 months AND bicalutamide OR flutamide is given orally daily for a total duration of 16 weeks. Beginning with week 9, patients undergo radiotherapy 5 days a week for 8 weeks. * Arm II: Patients receive total androgen suppression for 28 weeks prior to the initiation of radiotherapy and throughout radiotherapy. An LHRH agonist AND bicalutamide OR flutamide are administered as in arm I for a total duration of 36 weeks. Beginning with week 29, patients undergo radiotherapy as in arm I. Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 1,540 patients (770 per treatment arm) will be accrued for this study within 4 years.

Source references

references

citation
Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015 Feb 1;33(4):332-9. doi: 10.1200/JCO.2014.58.0662. Epub 2014 Dec 22.
pmid
25534388
type
RESULT
citation
Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng FY. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. NEJM Evid. 2023 Aug;2(8):EVIDoa2300023. doi: 10.1056/EVIDoa2300023. Epub 2023 Jun 29.
pmid
38320143
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-7ad944f6deaf1f5cd6122126
edge id
nct-edge-2562e4fa2907fee93da2
requested nct id
NCT00005044
primary nct id
NCT00005044
source kind
nci_explicit_reference_or_link
source url
https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq
source record id
Source null
source file sha256
89c3cbcb10a3e14c5ee4b607046c929e5902a798e71e758f8a712b0ae71413cf
payload sha256
4f162c77475d6bb43ed0e971312a5c4945254e5c3ae3e5289be731dc25113026
payload
clinical indication matching status
not_inferred
end exclusive
true
id
nct-edge-2562e4fa2907fee93da2
link basis
explicit_NCT_identifier_in_acquired_source
nct id
NCT00005044
occurrences
context exact
.48–0.83, <em>P</em> = .0008).</li></ul></div></li><li>The duration of neoadjuvant hormonal therapy was tested in another trial (<a href="/clinicaltrials/NCT00005044">RTOG-9910</a> [NCT00005044]) of 1,489 eligible men with intermediate-risk prostate cancer (T1b–4, Gleason score 2–6, and PSA >10 but ≤100
end
346540
exact text
NCT00005044
start
346529
context exact
.0008).</li></ul></div></li><li>The duration of neoadjuvant hormonal therapy was tested in another trial (<a href="/clinicaltrials/NCT00005044">RTOG-9910</a> [NCT00005044]) of 1,489 eligible men with intermediate-risk prostate cancer (T1b–4, Gleason score 2–6, and PSA >10 but ≤100 ng/mL; T1b–4, Gleason
end
346568
exact text
NCT00005044
start
346557
context exact
.48–0.83, <em>P</em> = .0008).</li></ul></div></li><li>The duration of neoadjuvant hormonal therapy was tested in another trial (<a href="/clinicaltrials/NCT00005044">RTOG-9910</a> [NCT00005044]) of 1,489 eligible men with intermediate-risk prostate cancer (T1b–4, Gleason score 2–6, and PSA >10 but ≤100
end
401144
exact text
NCT00005044
start
401133
context exact
.0008).</li></ul></div></li><li>The duration of neoadjuvant hormonal therapy was tested in another trial (<a href="/clinicaltrials/NCT00005044">RTOG-9910</a> [NCT00005044]) of 1,489 eligible men with intermediate-risk prostate cancer (T1b–4, Gleason score 2–6, and PSA >10 but ≤100 ng/mL; T1b–4, Gleason
end
401172
exact text
NCT00005044
start
401161
context exact
.48–0.83, <em>P</em> = .0008).</li></ul></div></li><li>The duration of neoadjuvant hormonal therapy was tested in another trial (<a href="/clinicaltrials/NCT00005044">RTOG-9910</a> [NCT00005044]) of 1,489 eligible men with intermediate-risk prostate cancer (T1b–4, Gleason score 2–6, and PSA >10 but ≤100
end
497707
exact text
NCT00005044
start
497696
context exact
.0008).</li></ul></div></li><li>The duration of neoadjuvant hormonal therapy was tested in another trial (<a href="/clinicaltrials/NCT00005044">RTOG-9910</a> [NCT00005044]) of 1,489 eligible men with intermediate-risk prostate cancer (T1b–4, Gleason score 2–6, and PSA >10 but ≤100 ng/mL; T1b–4, Gleason
end
497735
exact text
NCT00005044
start
497724
offset unit
unicode_code_points
source file
/tmp/cancer-full-research/nci/raw/48a3f061dd2bbd22e8.html
source file sha256
89c3cbcb10a3e14c5ee4b607046c929e5902a798e71e758f8a712b0ae71413cf
source json pointer
Source null
source kind
nci_explicit_reference_or_link
source record id
Source null
source retrieved at
2026-09-09T23:22:14.334045+00:00
source string basis
UTF-8_text_with_universal_newline_translation
source string sha256
351f45145a6c8591cdadd072763243033f8e1fa33cafecd55e4bac86e2b9edf3
source title
Prostate Cancer Treatment (PDQ®)–Health Professional Version
source update dates
context
Updated: May 14, 2025
datetime
2025-05-14T12:00:00Z
display
May 14, 2025
source url
https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq

Preserved source evidence · Not medical advice